USPTO Art Unit 1643 Prosecution Statistics

Art Unit Information

Art Unit: 1643
Group: 1640
Tech Center: 1600
Total Cases: 10,788
Last Active: January 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19036915ANTIBODIES THAT BIND TNFRSF25January 2025April 2025Allow300YesNo
19032739MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIESJanuary 2025April 2025Allow300YesNo
19032782MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIESJanuary 2025April 2025Allow300YesNo
18987178ANTI-CD161 ANTIBODIES AND USES THEREOFDecember 2024February 2025Allow200NoNo
18919069ANTIGEN BINDING POLYPEPTIDESOctober 2024January 2025Allow300YesNo
18911506MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIESOctober 2024January 2025Allow410NoNo
18907087BINDING AGENTS AND METHODS OF USING THE SAMEOctober 2024March 2025Allow510YesNo
18905034TL1A ASSOCIATED ANTIBODY COMPOSITIONS AND METHODS OF USEOctober 2024April 2025Allow601YesNo
18887598ANTIBODIES SPECIFICALLY BINDING TO CD147 AND USES THEREOFSeptember 2024March 2025Allow610YesNo
18826183FUSION PROTEINS FOR IMMUNOTHERAPY AGAINST CANCER AND INFECTIOUS DISEASESSeptember 2024June 2025Allow910NoNo
18821737IMMUNOCONJUGATES AND METHODSAugust 2024December 2024Allow410YesNo
18821730IMMUNOCONJUGATES AND METHODSAugust 2024December 2024Allow410YesNo
18821707IMMUNOCONJUGATES AND METHODSAugust 2024December 2024Allow410YesNo
18821718IMMUNOCONJUGATES AND METHODSAugust 2024December 2024Allow410YesNo
18807087DIMERIC ANTIBODIESAugust 2024May 2025Allow920NoNo
18807097METHODS OF MANUFACTURING DIMERIC ANTIBODIESAugust 2024February 2025Allow610NoNo
18805883MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIESAugust 2024December 2024Allow410NoNo
18805937MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIESAugust 2024December 2024Allow410NoNo
18793279ANTIBODIES TARGETING CCR2August 2024September 2024Allow200NoNo
18774123DOSING REGIMEN FOR TREATING INFLAMMATORY BOWEL DISEASEJuly 2024April 2025Allow911YesNo
18755457ANTIBODIES BINDING TO FIBROBLAST ACTIVATION PROTEIN ALPHA AND DEATH RECEPTOR 4June 2024March 2025Allow910YesNo
18734892TAU BINDING COMPOUNDSJune 2024February 2025Allow810NoNo
18656234ANTIBODIES AND ANTIBODY-DRUG CONJUGATES TARGETING CLAUDIN 6May 2024August 2024Allow300NoNo
18654735POLYOXAZOLINE-DRUG CONJUGATES WITH NOVEL PHARMACOKINETIC PROPERTIESMay 2024April 2025Allow1120YesNo
18654902POLYOXAZOLINE-DRUG CONJUGATES WITH NOVEL PHARMACOKINETIC PROPERTIESMay 2024April 2025Allow1120YesNo
18643312BISPECIFIC OR-GATE CHIMERIC ANTIGEN RECEPTOR RESPONSIVE TO CD20 and CD19April 2024October 2024Allow621NoNo
18640982COMPOSITIONS TARGETING BCMA AND METHODS OF USE THEREOFApril 2024December 2024Allow800YesNo
18630058STING SENSITIZING AGENTSApril 2024April 2025Abandon1210NoNo
18623246BISPECIFIC OR-GATE CHIMERIC ANTIGEN RECEPTOR RESPONSIVE TO CD20 and CD19April 2024October 2024Allow720NoNo
18618626Bispecific Constructs for Target and Complement EngagementMarch 2024January 2025Allow1021YesNo
18612854CD19/CD38 MULTISPECIFIC ANTIBODIESMarch 2024September 2024Allow520YesNo
18611087HUMAN PD-L2 ANTIBODIES AND METHODS OF USE THEREFORMarch 2024May 2025Allow1410YesNo
18609032MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHYMarch 2024July 2024Allow410YesNo
18595279LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAMEMarch 2024April 2025Abandon1310NoNo
18595275LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAMEMarch 2024December 2024Abandon910NoNo
18590865SIRP ALPHA, SIRP BETA 1, AND SIRP GAMMA ANTIBODIES AND USES THEREOFFebruary 2024August 2024Allow610YesNo
18582950ANTI-CD161 ANTIBODIES AND USES THEREOFFebruary 2024September 2024Allow701YesNo
18432567METHOD OF MODIFYING ISOELECTRIC POINT OF ANTIBODY VIA AMINO ACID SUBSTITUTION IN CDRFebruary 2024August 2024Allow710NoNo
18429758CHIMERIC ANTIGEN RECEPTOR COMPOSITIONS AND METHODS FOR TREATING MUC1* DISEASESFebruary 2024August 2024Allow610NoNo
18425859METHOD OF MODIFYING ISOELECTRIC POINT OF ANTIBODY VIA AMINO ACID SUBSTITUTION IN CDRJanuary 2024August 2024Allow610YesNo
18575650ANTIGEN-BINDING POLYPEPTIDE TARGETING B7H3 AND APPLICATION THEREOFDecember 2023August 2024Allow810NoNo
18396466METHODS OF MANUFACTURING DIMERIC ANTIBODIESDecember 2023July 2024Allow710NoNo
18396418DIMERIC ANTIBODIESDecember 2023July 2024Allow710NoNo
18393322UNIVERSAL ANTI-CD22 CHIMERIC ANTIGEN RECEPTOR ENGINEERED IMMUNE CELLSDecember 2023July 2024Allow710NoNo
18517345Use of Combination of Anti-PD-1 Antibody and VEGFR Inhibitor in Preparation of Drug for Treating CancersNovember 2023May 2025Allow1820YesNo
18511818CEACAM5 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOFNovember 2023September 2024Abandon1010NoNo
18388036PD-1 Peptide InhibitorsNovember 2023March 2025Abandon1600NoNo
18503245PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-HUMAN TSLP RECEPTOR ANTIBODIES AND METHODS OF USING THE SAMENovember 2023July 2024Allow810NoNo
18559201COMPOSITIONS AND METHODS RELATED TO TUMOR ACTIVATED ANTIBODIES TARGETING EGFR AND EFFECTOR CELL ANTIGENSNovember 2023August 2024Allow910YesNo
18384508PD-ECGF AS BIOMARKER OF CANCEROctober 2023December 2024Allow1410YesNo
18495086MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHYOctober 2023February 2024Allow310NoNo
18494007HER-2 TARGETED BISPECIFIC COMPOSITIONS AND METHODS FOR MAKING AND USING THE SAMEOctober 2023December 2024Allow1320NoNo
18492311CANCER THERAPYOctober 2023December 2024Abandon1410NoNo
18492141IMMUNOSTIMULATORY AGENTS IN COMBINATION WITH ANGIOGENESIS INHIBITORSOctober 2023April 2025Abandon1810NoNo
18383043ANTI-CEACAM6 ANTIBODIES AND METHODS OF USEOctober 2023October 2024Allow1110NoNo
18491182CANINE MONOCLONAL ANTIBODIES AGAINST CANINE CYTOTOXIC T LYMPHOCYTE ASSOCIATED PROTEIN 4 (CTLA-4)October 2023June 2024Allow710NoNo
18481547METHODS OF USING RARy AGONISTS FOR CANCER TREATMENTOctober 2023June 2024Allow800YesNo
18479317IMMUNOCONJUGATES AND METHODSOctober 2023August 2024Allow1120NoNo
18475892HUMAN CD30-SPECIFIC BINDING PROTEINS AND USES THEREOFSeptember 2023June 2024Allow910NoNo
18473858METHODS OF TREATING UROTHELIAL CARCINOMA USING AN ANTI-PD-1 ANTIBODYSeptember 2023June 2025Abandon2020NoNo
18464998COMPOSITIONS AND METHODS RELATED TO IL27 RECEPTOR BINDINGSeptember 2023September 2024Allow1220NoNo
18464847HUMANIZED ANTI-CD45 ANTIBODIESSeptember 2023April 2024Allow701NoNo
18457239FUSOBACTERIUM NUCLEATUM AMYLOID-LIKE FADA FOR DIAGNOSIS AND TREATMENT OF FN-MEDIATED PATHOGENESISAugust 2023February 2024Allow600YesNo
18238210BISPECIFIC OR-GATE CHIMERIC ANTIGEN RECEPTOR RESPONSIVE TO CD19 and CD20August 2023February 2024Allow510YesNo
18454286Anti-SIRP-Alpha Antibodies and Methods of Use ThereofAugust 2023October 2024Allow1410NoNo
18451047MULTISPECIFIC ANTI-TCR DELTA VARIABLE 1 ANTIBODIESAugust 2023January 2025Allow1711YesNo
18449190METHODAugust 2023April 2024Allow810YesNo
18361184SIGLEC-8 BINDING PROTEINS AND USES THEREOFJuly 2023May 2024Abandon910YesNo
18227828LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAMEJuly 2023April 2025Abandon2110NoNo
18349337ANTI-ROR1 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI ROR1 ANTIBODY CONJUGATES, AND METHODS OF MAKING AND USING ANTI-ROR1 ANTIBODY CONJUGATESJuly 2023September 2024Allow1421NoNo
18345892ANTI-ROR1 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI ROR1 ANTIBODY CONJUGATES, AND METHODS OF MAKING AND USING ANTI-ROR1 ANTIBODY CONJUGATESJune 2023July 2024Allow1311YesNo
18344653Methods and Compositions for Treating Cancers by Inhibiting Estrogen Signaling in Myeloid-Derived Suppressor CellsJune 2023February 2025Abandon1911YesNo
18216085Anti-Axl Antagonistic AntibodiesJune 2023October 2024Abandon1610NoNo
18330740RECOMBINANT POLYPEPTIDES AND METHODS OF USE THEREOFJune 2023April 2025Abandon2201NoNo
18330367TIM-3-TARGETING ANTIBODIES AND USES THEREOFJune 2023June 2024Allow1221YesNo
18329781MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHYJune 2023September 2023Allow410YesNo
18255880B7-H3 TARGETING ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOFJune 2023December 2024Abandon1820NoNo
18256045TROP2 TARGETING ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD AND USE THEREFORJune 2023December 2024Abandon1820NoNo
18255814CHIMERIC ANTIGEN RECEPTOR COMPRISING ANTI-MESOTHELIN SCFV, AND USE THEREOFJune 2023November 2023Allow600YesNo
18254882ANTIBODY-DRUG CONJUGATE, AND INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOFMay 2023October 2024Allow1730NoNo
18318384COVALENTLY-MODIFIED STEROID ACID-PEPTIDES HAVING ENHANCED STABILITY AND/OR BIOLOGICAL ACTIVITYMay 2023October 2024Allow1710NoNo
18315686MONOCLONAL ANTIBODIES DIRECTED AGAINST PROGRAMMED DEATH-1 PROTEIN AND THEIR USE IN MEDICINEMay 2023November 2023Allow610NoNo
18314091Antigen Binding Molecules Targeting SARS-CoV-2May 2023October 2023Abandon610NoNo
18313306Antigen Binding Molecules Targeting SARS-CoV-2May 2023December 2023Allow710NoNo
18139826TREATMENT OF CANCER USING A SMAD3 INHIBITORApril 2023June 2025Abandon2621YesNo
18307299ANTIBODIES BINDING BCMA AND CD3 AND USES THEREOFApril 2023May 2024Allow1211NoNo
18131559METHODS AND COMPOSITIONS FOR DETERMINING THE FUNCTIONAL ACTIVITY OF DNA DOUBLE STRAND BREAK REPAIR PATHWAY MOLECULES FOR ASSESSING GERMLINE RISK OF CANCERApril 2023November 2024Allow1921NoNo
18191372Method And MoleculesMarch 2023March 2025Abandon2421NoNo
18184120BINDING AGENTS BINDING TO EPCAM AND CD137March 2023April 2025Allow2541YesYes
18121975METHOD AND DEVICE FOR PURIFICATION OF BLOOD FROM CIRCULATING CELL FREE DNAMarch 2023August 2023Allow510NoNo
18183840BISPECIFIC GPC3xCD28 AND GPC3xCD3 ANTIBODIES AND THEIR COMBINATION FOR TARGETED KILLING OF GPC3 POSITIVE MALIGNANT CELLSMarch 2023June 2024Allow1510YesNo
18119103PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF CANCERMarch 2023October 2024Abandon2010NoNo
18173413LINKERS FOR ANTIBODY DRUG CONJUGATESFebruary 2023May 2024Allow1410NoNo
18172123ANTI-CD228 ANTIBODIES AND ANTIBODY-DRUG CONJUGATESFebruary 2023June 2024Abandon1610NoNo
18169174DENDRITIC CELL TUMOR VACCINE AND USES THEREOFFebruary 2023June 2024Allow1640YesNo
18164514HEAVY CHAIN ANTIBODIES BINDING TO PSMAFebruary 2023September 2023Allow710NoNo
18164386COMPOSITIONS AND METHODS RELATED TO IL27 RECEPTOR BINDINGFebruary 2023August 2023Allow710YesNo
18164519ANTI-CCR7 ANTIBODY DRUG CONJUGATESFebruary 2023July 2024Allow1810NoNo
17803947Antiaging effect of Intradermal Administration of Immune Checkpoint InhibitorsJanuary 2023September 2024Abandon1910NoNo
18103740SAPOSIN-A DERIVED PEPTIDES AND USES THEREOFJanuary 2023December 2024Allow2311NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1643.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
110
Examiner Affirmed
70
(63.6%)
Examiner Reversed
40
(36.4%)
Reversal Percentile
68.5%
Higher than average

What This Means

With a 36.4% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
1011
Allowed After Appeal Filing
203
(20.1%)
Not Allowed After Appeal Filing
808
(79.9%)
Filing Benefit Percentile
6.4%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 20.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1643 - Prosecution Statistics Summary

Executive Summary

Art Unit 1643 is part of Group 1640 in Technology Center 1600. This art unit has examined 10,788 patent applications in our dataset, with an overall allowance rate of 54.6%. Applications typically reach final disposition in approximately 35 months.

Comparative Analysis

Art Unit 1643's allowance rate of 54.6% places it in the 10% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1643 receive an average of 1.91 office actions before reaching final disposition (in the 58% percentile). The median prosecution time is 35 months (in the 19% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With more office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.